Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stevo Julius

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
Blood Pressure|October 30, 2015
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trialSverre E Kjeldsen, Eivind Berge, Sripal Bangalore, et al.
Hypertension (Dallas, Tex. : 1979)|June 3, 2004
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patientsPeter M Okin, Richard B Devereux, Markku S Nieminen, et al.
American Journal of Hypertension|July 10, 2003
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular riskStevo Julius, Sverre E Kjeldsen, Hans Brunner, et al.
Circulation. Arrhythmia and Electrophysiology|October 8, 2009
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE studyPeter M Okin, Kristian Wachtell, Sverre E Kjeldsen, et al.
Circulation|July 30, 2003
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) StudyPeter M Okin, Richard B Devereux, Sverker Jern, et al.
Journal of Hypertension|September 27, 2012
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapyMichael A Weber, Stevo Julius, Sverre E Kjeldsen, et al.
Circulation|March 15, 2006
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension StudyPeter M Okin, Richard B Devereux, Eva Gerdts, et al.
Journal of the American College of Cardiology|March 1, 2005
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyKristian Wachtell, Mika Lehto, Eva Gerdts, et al.
Hypertension (Dallas, Tex. : 1979)|June 23, 2023
Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm HgSondre Heimark, Maria H Mehlum, Giuseppe Mancia, et al.
Blood Pressure|January 6, 2021
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular riskEirik Olsen, Björn Holzhauer, Stevo Julius, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Blood Pressure|October 30, 2015
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trialSverre E Kjeldsen, Eivind Berge, Sripal Bangalore, et al.
Hypertension (Dallas, Tex. : 1979)|June 3, 2004
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patientsPeter M Okin, Richard B Devereux, Markku S Nieminen, et al.
American Journal of Hypertension|July 10, 2003
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular riskStevo Julius, Sverre E Kjeldsen, Hans Brunner, et al.
Circulation. Arrhythmia and Electrophysiology|October 8, 2009
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE studyPeter M Okin, Kristian Wachtell, Sverre E Kjeldsen, et al.
Circulation|July 30, 2003
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) StudyPeter M Okin, Richard B Devereux, Sverker Jern, et al.
Journal of Hypertension|September 27, 2012
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapyMichael A Weber, Stevo Julius, Sverre E Kjeldsen, et al.
Circulation|March 15, 2006
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension StudyPeter M Okin, Richard B Devereux, Eva Gerdts, et al.
Journal of the American College of Cardiology|March 1, 2005
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyKristian Wachtell, Mika Lehto, Eva Gerdts, et al.
Hypertension (Dallas, Tex. : 1979)|June 23, 2023
Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm HgSondre Heimark, Maria H Mehlum, Giuseppe Mancia, et al.
Blood Pressure|January 6, 2021
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular riskEirik Olsen, Björn Holzhauer, Stevo Julius, et al.
Pageof 12